Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients

(Spink Health) New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news